Lilly Wants To Gamble On Dice’s Oral IL-17 Drugs For Psoriasis
Lilly agrees to pay about $2.4bn to acquire Dice and its Phase IIb oral IL-17 inhibitor, as well as a discovery platform that has yielded a preclinical oral PD-L1 inhibitor.
Lilly agrees to pay about $2.4bn to acquire Dice and its Phase IIb oral IL-17 inhibitor, as well as a discovery platform that has yielded a preclinical oral PD-L1 inhibitor.